{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:21:46Z","timestamp":1772202106154,"version":"3.50.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Being a disease with heterogeneous presentations and unclear consensus on its diagnostic criteria, it is difficult to differentiate vascular parkinsonism (VaP) from other neurodegenerative parkinsonism variants. Ongoing research on structural and functional neuroimaging targeting dopaminergic pathway provides us more insight into the pathophysiology of VaP to improve diagnostic accuracy. The aim of this article is to review how the emerging imaging modalities help the diagnostic process and treatment decision in VaP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Dopamine transporter imaging is a promising tool in differentiating presynaptic parkinsonism and VaP. It also predicts the levodopa responders in VaP. Advanced MRI techniques including volumetry, diffusion tensor imaging and sequences visualising substantia nigra are under development, and they are complementary to each other in detecting structural and functional changes in VaP, which is crucial to ensure the quality of future therapeutic trials for VaP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Dopamine transporter imaging is recommended to patients with suspected VaP. Multimodal MRI in VaP would be an important area to be investigated in the near future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11910-019-1019-7","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T14:02:42Z","timestamp":1574776962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Neuroimaging in Vascular Parkinsonism"],"prefix":"10.1007","volume":"19","author":[{"given":"Karen K. Y.","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent C. T.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"1019_CR1","first-page":"124","volume":"2","author":"WJ Weiner","year":"2005","unstructured":"Weiner WJ. A differential diagnosis of parkinsonism. Rev Neurol Dis. 2005;2:124\u201331.","journal-title":"Rev Neurol Dis"},{"key":"1019_CR2","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670\u20136.","journal-title":"Neurology"},{"key":"1019_CR3","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1212\/WNL.44.11.2015","volume":"44","author":"JJ Hauw","year":"1994","unstructured":"Hauw JJ, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994;44:2015\u20139.","journal-title":"Neurology"},{"key":"1019_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601.","journal-title":"Mov Disord"},{"key":"1019_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1\u20139.","journal-title":"Neurology"},{"key":"1019_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","volume":"8","author":"DR Williams","year":"2009","unstructured":"Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009;8:270\u20139.","journal-title":"Lancet Neurol"},{"key":"1019_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/WNL.48.2.384","volume":"48","author":"Y Ben-Shlomo","year":"1997","unstructured":"Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology. 1997;48:384\u201393.","journal-title":"Neurology"},{"key":"1019_CR8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","volume":"130","author":"LI Golbe","year":"2007","unstructured":"Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130:1552\u201365.","journal-title":"Brain"},{"key":"1019_CR9","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1002\/mds.23192","volume":"25","author":"M Kollensperger","year":"2010","unstructured":"Kollensperger M, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord. 2010;25:2604\u201312.","journal-title":"Mov Disord"},{"key":"1019_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s100720100021","volume":"22","author":"D Testa","year":"2001","unstructured":"Testa D, et al. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci. 2001;22:247\u201351.","journal-title":"Neurol Sci"},{"key":"1019_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/jnnp.60.2.213","volume":"60","author":"V Bocola","year":"1996","unstructured":"Bocola V, Fabbrini G, Sollecito A, Paladini C, Martucci N. Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs. J Neurol Neurosurg Psychiatry. 1996;60:213\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1019_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/mds.27050","volume":"32","author":"JH Friedman","year":"2017","unstructured":"Friedman JH. Drug-induced parkinsonism. Mov Disord. 2017;32:1111.","journal-title":"Mov Disord"},{"key":"1019_CR13","first-page":"293","volume":"12","author":"A Gironell","year":"1997","unstructured":"Gironell A, Lopez-Villegas D, Barbanoj M, Kulisevsky J. Psychogenic tremor: clinical, electrophysiologic and psychopathologic assessment. Neurologia. 1997;12:293\u20139.","journal-title":"Neurologia"},{"key":"1019_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(05)70285-4","volume":"5","author":"E Tolosa","year":"2006","unstructured":"Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson\u2019s disease. Lancet Neurol. 2006;5:75\u201386.","journal-title":"Lancet Neurol"},{"key":"1019_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00401-003-0676-3","volume":"105","author":"KA Jellinger","year":"2003","unstructured":"Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson\u2019s disease. A postmortem study. Acta Neuropathol. 2003;105:415\u20139.","journal-title":"Acta Neuropathol"},{"key":"1019_CR16","unstructured":"Arteriosclerotic parkinsonism. Edinb Med J. 1930;37:261\u20132."},{"key":"1019_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mds.20083","volume":"19","author":"JC Zijlmans","year":"2004","unstructured":"Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004;19:630\u201340.","journal-title":"Mov Disord"},{"key":"1019_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/mds.870040306","volume":"4","author":"PM FitzGerald","year":"1989","unstructured":"FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989;4:249\u201360.","journal-title":"Mov Disord"},{"key":"1019_CR19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/jnnp-2014-307867","volume":"86","author":"TC Vale","year":"2015","unstructured":"Vale TC, Caramelli P, Cardoso F. Clinicoradiological comparison between vascular parkinsonism and Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2015;86:547\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1019_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/mds.22937","volume":"25","author":"S Kalra","year":"2010","unstructured":"Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson\u2019s disease: a systematic review. Mov Disord. 2010;25:149\u201356.","journal-title":"Mov Disord"},{"key":"1019_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrneurol.2015.61","volume":"11","author":"AD Korczyn","year":"2015","unstructured":"Korczyn AD. Vascular parkinsonism--characteristics, pathogenesis and treatment. Nat Rev Neurol. 2015;11:319\u201326.","journal-title":"Nat Rev Neurol"},{"key":"1019_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2017.12.030","volume":"49","author":"I Rektor","year":"2018","unstructured":"\u2022\u2022 Rektor I, et al. An updated diagnostic approach to subtype definition of vascular parkinsonism - recommendations from an expert working group. Parkinsonism Relat Disord. 2018;49:9\u201316 This article provides a comprehensive overview on VaP, in particular the clinical features. It also gives updated and clear definition of different subtype of VaP from the consensus of a large expert working group.","journal-title":"Parkinsonism Relat Disord"},{"key":"1019_CR23","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/mds.26263","volume":"30","author":"JA Vizcarra","year":"2015","unstructured":"Vizcarra JA, Lang AE, Sethi KD, Espay AJ. Vascular parkinsonism: deconstructing a syndrome. Mov Disord. 2015;30:886\u201394.","journal-title":"Mov Disord"},{"key":"1019_CR24","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","volume":"12","author":"JM Wardlaw","year":"2013","unstructured":"Wardlaw JM, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822\u201338.","journal-title":"Lancet Neurol"},{"key":"1019_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00401-009-0620-2","volume":"119","author":"SA Choi","year":"2010","unstructured":"Choi SA, et al. Are there differences in cerebral white matter lesion burdens between Parkinson\u2019s disease patients with or without dementia? Acta Neuropathol. 2010;119:147\u20139.","journal-title":"Acta Neuropathol"},{"key":"1019_CR26","first-page":"55","volume":"86","author":"KA Jellinger","year":"2001","unstructured":"Jellinger KA. The pathology of Parkinson\u2019s disease. Adv Neurol. 2001;86:55\u201372.","journal-title":"Adv Neurol"},{"key":"1019_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/NEN.0b013e3181d88e63","volume":"69","author":"E Ghebremedhin","year":"2010","unstructured":"Ghebremedhin E, et al. Inverse relationship between cerebrovascular lesions and severity of lewy body pathology in patients with lewy body diseases. J Neuropathol Exp Neurol. 2010;69:442\u20138.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1019_CR28","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1212\/WNL.0000000000002082","volume":"85","author":"HM van der Holst","year":"2015","unstructured":"van der Holst HM, et al. Cerebral small vessel disease and incident parkinsonism: the RUN DMC study. Neurology. 2015;85:1569\u201377.","journal-title":"Neurology"},{"key":"1019_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nrneurol.2011.21","volume":"7","author":"NI Bohnen","year":"2011","unstructured":"Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nat Rev Neurol. 2011;7:229\u201336.","journal-title":"Nat Rev Neurol"},{"key":"1019_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1750-3639.2012.00611.x","volume":"23","author":"J Horvath","year":"2013","unstructured":"Horvath J, Burkhard PR, Bouras C, Kovari E. Etiologies of parkinsonism in a century-long autopsy-based cohort. Brain Pathol. 2013;23:28\u201333.","journal-title":"Brain Pathol"},{"key":"1019_CR31","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1136\/jnnp-2012-302828","volume":"83","author":"PG Glass","year":"2012","unstructured":"Glass PG, et al. The clinical features of pathologically confirmed vascular parkinsonism. J Neurol Neurosurg Psychiatry. 2012;83:1027\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1019_CR32","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/mds.10202","volume":"17","author":"JH Bower","year":"2002","unstructured":"Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord. 2002;17:910\u20136.","journal-title":"Mov Disord"},{"key":"1019_CR33","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/brain\/awf080","volume":"125","author":"AJ Hughes","year":"2002","unstructured":"Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861\u201370.","journal-title":"Brain"},{"key":"1019_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1212\/WNL.48.1.119","volume":"48","author":"I Litvan","year":"1997","unstructured":"Litvan I, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997;48:119\u201325.","journal-title":"Neurology"},{"key":"1019_CR35","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1001\/archneur.59.10.1597","volume":"59","author":"KA Josephs","year":"2002","unstructured":"Josephs KA, Ishizawa T, Tsuboi Y, Cookson N, Dickson DW. A clinicopathological study of vascular progressive supranuclear palsy: a multi-infarct disorder presenting as progressive supranuclear palsy. Arch Neurol. 2002;59:1597\u2013601.","journal-title":"Arch Neurol"},{"key":"1019_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mds.22977","volume":"25","author":"DR Williams","year":"2010","unstructured":"Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord. 2010;25:357\u201362.","journal-title":"Mov Disord"},{"key":"1019_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-3-7091-6641-3_15","volume":"42","author":"J Winikates","year":"1994","unstructured":"Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl. 1994;42:189\u2013201.","journal-title":"J Neural Transm Suppl"},{"key":"1019_CR38","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1161\/01.STR.28.5.965","volume":"28","author":"H Yamanouchi","year":"1997","unstructured":"Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke. 1997;28:965\u20139.","journal-title":"Stroke"},{"key":"1019_CR39","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WM Schuepbach","year":"2013","unstructured":"Schuepbach WM, et al. Neurostimulation for Parkinson\u2019s disease with early motor complications. N Engl J Med. 2013;368:610\u201322.","journal-title":"N Engl J Med"},{"key":"1019_CR40","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1002\/mds.21648","volume":"22","author":"LC Shih","year":"2007","unstructured":"Shih LC, Tarsy D. Deep brain stimulation for the treatment of atypical parkinsonism. Mov Disord. 2007;22:2149\u201355.","journal-title":"Mov Disord"},{"key":"1019_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.nic.2009.08.006","volume":"20","author":"JC Zijlmans","year":"2010","unstructured":"Zijlmans JC. The role of imaging in the diagnosis of vascular parkinsonism. Neuroimaging Clin N Am. 2010;20:69\u201376.","journal-title":"Neuroimaging Clin N Am"},{"key":"1019_CR42","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000326907","volume":"65","author":"SM Choi","year":"2011","unstructured":"Choi SM, et al. Midbrain atrophy in vascular parkinsonism. Eur Neurol. 2011;65:296\u2013301.","journal-title":"Eur Neurol"},{"key":"1019_CR43","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00415-017-8561-5","volume":"264","author":"V Dunet","year":"2017","unstructured":"\u2022 Dunet V, et al. MRI volumetric morphometry in vascular parkinsonism. J Neurol. 2017;264:1511\u20139 This MRI volumetry study demonstrated the caudate volume and WMH volume is helpful to differentiate VaP from IPD and healthy controls.","journal-title":"J Neurol"},{"key":"1019_CR44","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10072-017-2812-1","volume":"38","author":"BC Kim","year":"2017","unstructured":"\u2022 Kim BC, et al. MRI measurements of brainstem structures in patients with vascular parkinsonism, progressive supranuclear palsy, and Parkinson\u2019s disease. Neurol Sci. 2017;38:627\u201333 This MRI volumetry study suggests midbrain to pons ratio is helpful to distinguish VaP from IPD and PSP.","journal-title":"Neurol Sci"},{"key":"1019_CR45","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10072-016-2489-x","volume":"37","author":"G Mostile","year":"2016","unstructured":"\u2022 Mostile G, et al. Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism. Neurol Sci. 2016;37:591\u20135 This is the first MRI volumetry study on VaP, which demonstrated MRPI is useful to differentiate VaP from PSP.","journal-title":"Neurol Sci"},{"key":"1019_CR46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1001\/archneur.56.1.98","volume":"56","author":"J Winikates","year":"1999","unstructured":"Winikates J. J.J. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999;56:114\u20139.","journal-title":"Arch Neurol"},{"key":"1019_CR47","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1212\/WNL.45.12.2183","volume":"45","author":"JC Zijlmans","year":"1995","unstructured":"Zijlmans JC, et al. MRI in patients with suspected vascular parkinsonism. Neurology. 1995;45:2183\u20138.","journal-title":"Neurology"},{"key":"1019_CR48","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/archneurol.2012.633","volume":"69","author":"HC Wang","year":"2012","unstructured":"Wang HC, Hsu JL, Leemans A. Diffusion tensor imaging of vascular parkinsonism: structural changes in cerebral white matter and the association with clinical severity. Arch Neurol. 2012;69:1340\u20138.","journal-title":"Arch Neurol"},{"key":"1019_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/jnnp-2012-302618","volume":"84","author":"S Benitez-Rivero","year":"2013","unstructured":"Benitez-Rivero S, et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2013;84:122\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1019_CR50","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/mds.10092","volume":"17","author":"W Gerschlager","year":"2002","unstructured":"Gerschlager W, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson\u2019s disease. Mov Disord. 2002;17:518\u201323.","journal-title":"Mov Disord"},{"key":"1019_CR51","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/mds.21479","volume":"22","author":"J Zijlmans","year":"2007","unstructured":"Zijlmans J, et al. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson\u2019s disease. Mov Disord. 2007;22:1278\u201385.","journal-title":"Mov Disord"},{"key":"1019_CR52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351\u20136.","journal-title":"AJR Am J Roentgenol"},{"key":"1019_CR53","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/mds.870120642","volume":"12","author":"G Fenelon","year":"1997","unstructured":"Fenelon G, Houeto JL. Unilateral parkinsonism following a large infarct in the territory of the lenticulostriate arteries. Mov Disord. 1997;12:1086\u201390.","journal-title":"Mov Disord"},{"key":"1019_CR54","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1161\/01.STR.32.1.258","volume":"32","author":"JS Kim","year":"2001","unstructured":"Kim JS. Involuntary movements after anterior cerebral artery territory infarction. Stroke. 2001;32:258\u201361.","journal-title":"Stroke"},{"key":"1019_CR55","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1212\/WNL.40.6.897","volume":"40","author":"RW Murrow","year":"1990","unstructured":"Murrow RW, Schweiger GD, Kepes JJ, Koller WC. Parkinsonism due to a basal ganglia lacunar state: clinicopathologic correlation. Neurology. 1990;40:897\u2013900.","journal-title":"Neurology"},{"key":"1019_CR56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fnins.2015.00101","volume":"9","author":"A Garg","year":"2015","unstructured":"Garg A, Appel-Cresswell S, Popuri K, McKeown MJ, Beg MF. Morphological alterations in the caudate, putamen, pallidum, and thalamus in Parkinson\u2019s disease. Front Neurosci. 2015;9:101.","journal-title":"Front Neurosci"},{"key":"1019_CR57","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3174\/ajnr.A2372","volume":"32","author":"SH Lee","year":"2011","unstructured":"Lee SH, et al. Regional volume analysis of the Parkinson disease brain in early disease stage: gray matter, white matter, striatum, and thalamus. AJNR Am J Neuroradiol. 2011;32:682\u20137.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1019_CR58","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/mds.26471","volume":"31","author":"G Barbagallo","year":"2016","unstructured":"Barbagallo G, et al. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord. 2016;31:325\u201334.","journal-title":"Mov Disord"},{"key":"1019_CR59","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.parkreldis.2010.12.010","volume":"17","author":"D Messina","year":"2011","unstructured":"Messina D, et al. Patterns of brain atrophy in Parkinson\u2019s disease, progressive supranuclear palsy and multiple system atrophy. Parkinsonism Relat Disord. 2011;17:172\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"1019_CR60","unstructured":"Ma K, Shi ACL, Abrigo J, Cheung T, Lau C, Mok V. MRI volumetrics in parkinsonian syndromes [abstract]. Mov Disord. 2018;33."},{"key":"1019_CR61","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s007020070006","volume":"107","author":"R Asato","year":"2000","unstructured":"Asato R, Akiguchi I, Masunaga S, Hashimoto N. Magnetic resonance imaging distinguishes progressive supranuclear palsy from multiple system atrophy. J Neural Transm (Vienna). 2000;107:1427\u201336.","journal-title":"J Neural Transm (Vienna)"},{"key":"1019_CR62","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/mds.23293","volume":"26","author":"G Longoni","year":"2011","unstructured":"Longoni G, et al. MRI measurements of brainstem structures in patients with Richardson\u2019s syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease. Mov Disord. 2011;26:247\u201355.","journal-title":"Mov Disord"},{"key":"1019_CR63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/jnnp.2005.075713","volume":"77","author":"A Padovani","year":"2006","unstructured":"Padovani A, et al. Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2006;77:457\u201363.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1019_CR64","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1001\/archneur.58.7.1076","volume":"58","author":"M Warmuth-Metz","year":"2001","unstructured":"Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol. 2001;58:1076\u20139.","journal-title":"Arch Neurol"},{"key":"1019_CR65","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1212\/01.WNL.0000437347.92583.fc","volume":"81","author":"G Arabia","year":"2013","unstructured":"Arabia G, Quattrone A. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology. 2013;81:2147.","journal-title":"Neurology"},{"key":"1019_CR66","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1148\/radiol.2453061703","volume":"246","author":"A Quattrone","year":"2008","unstructured":"Quattrone A, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology. 2008;246:214\u201321.","journal-title":"Radiology"},{"key":"1019_CR67","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/mds.23529","volume":"26","author":"M Morelli","year":"2011","unstructured":"Morelli M, et al. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov Disord. 2011;26:527\u201333.","journal-title":"Mov Disord"},{"key":"1019_CR68","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1212\/01.WNL.0000165960.04422.D0","volume":"64","author":"H Oba","year":"2005","unstructured":"Oba H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology. 2005;64:2050\u20135.","journal-title":"Neurology"},{"key":"1019_CR69","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jns.2014.09.002","volume":"346","author":"YF Chen","year":"2014","unstructured":"Chen YF, et al. The relationship of leukoaraiosis and the clinical severity of vascular Parkinsonism. J Neurol Sci. 2014;346:255\u20139.","journal-title":"J Neurol Sci"},{"key":"1019_CR70","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1161\/01.STR.0000038424.70926.5E","volume":"33","author":"L Pantoni","year":"2002","unstructured":"Pantoni L, et al. Visual rating scales for age-related white matter changes (leukoaraiosis): can the heterogeneity be reduced? Stroke. 2002;33:2827\u201333.","journal-title":"Stroke"},{"key":"1019_CR71","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000007921","volume":"39","author":"P Scheltens","year":"1998","unstructured":"Scheltens P, et al. White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol. 1998;39:80\u20139.","journal-title":"Eur Neurol"},{"key":"1019_CR72","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s00429-014-0804-y","volume":"220","author":"E Abela","year":"2015","unstructured":"Abela E, et al. Grey matter volumetric changes related to recovery from hand paresis after cortical sensorimotor stroke. Brain Struct Funct. 2015;220:2533\u201350.","journal-title":"Brain Struct Funct"},{"key":"1019_CR73","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0022-510X(97)00166-4","volume":"152","author":"I Aiba","year":"1997","unstructured":"Aiba I, et al. Relationship between brainstem MRI and pathological findings in progressive supranuclear palsy--study in autopsy cases. J Neurol Sci. 1997;152:210\u20137.","journal-title":"J Neurol Sci"},{"key":"1019_CR74","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1212\/WNL.0b013e318284070c","volume":"80","author":"CJ Cochrane","year":"2013","unstructured":"Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology. 2013;80:857\u201364.","journal-title":"Neurology"},{"key":"1019_CR75","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.neuroimage.2003.12.005","volume":"21","author":"MF Schocke","year":"2004","unstructured":"Schocke MF, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. Neuroimage. 2004;21:1443\u201351.","journal-title":"Neuroimage"},{"key":"1019_CR76","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.nicl.2018.09.028","volume":"20","author":"AS Talai","year":"2018","unstructured":"Talai AS, Sedlacik J, Boelmans K, Forkert ND. Widespread diffusion changes differentiate Parkinson\u2019s disease and progressive supranuclear palsy. Neuroimage Clin. 2018;20:1037\u201343.","journal-title":"Neuroimage Clin"},{"key":"1019_CR77","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.neurobiolaging.2014.07.048","volume":"36","author":"SM Maniega","year":"2015","unstructured":"Maniega SM, et al. White matter hyperintensities and normal-appearing white matter integrity in the aging brain. Neurobiol Aging. 2015;36:909\u201318.","journal-title":"Neurobiol Aging"},{"key":"1019_CR78","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.parkreldis.2019.02.046","volume":"63","author":"M Salsone","year":"2019","unstructured":"\u2022 Salsone M, et al. Microstructural changes of normal-appearing white matter in vascular parkinsonism. Parkinsonism Relat Disord. 2019;63:60\u20135 This is a recent study which helps to improve the understanding of white matter pathology in VaP with the use of DTI, even before visible white matter lesions appear.","journal-title":"Parkinsonism Relat Disord"},{"key":"1019_CR79","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1471-4159.1991.tb08170.x","volume":"56","author":"EC Hirsch","year":"1991","unstructured":"Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson\u2019s disease: an X-ray microanalysis. J Neurochem. 1991;56:446\u201351.","journal-title":"J Neurochem"},{"key":"1019_CR80","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/j.1471-4159.1989.tb07264.x","volume":"52","author":"DT Dexter","year":"1989","unstructured":"Dexter DT, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson\u2019s disease. J Neurochem. 1989;52:1830\u20136.","journal-title":"J Neurochem"},{"issue":"Pt 2","key":"1019_CR81","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/brain\/123.2.366","volume":"123","author":"N Kubis","year":"2000","unstructured":"Kubis N, et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain. 2000;123(Pt 2):366\u201373.","journal-title":"Brain"},{"key":"1019_CR82","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.1977.00500130053010","volume":"34","author":"PL McGeer","year":"1977","unstructured":"McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol. 1977;34:33\u20135.","journal-title":"Arch Neurol"},{"key":"1019_CR83","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/jnnp.54.1.30","volume":"54","author":"B Pakkenberg","year":"1991","unstructured":"Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson\u2019s disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry. 1991;54:30\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1019_CR84","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/mds.26932","volume":"32","author":"P Mahlknecht","year":"2017","unstructured":"\u2022 Mahlknecht P, Krismer F, Poewe W, Seppi K. Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson\u2019s disease. Mov Disord. 2017;32:619\u201323 This recent meta-analysis provides a comprehesive summary of the features of dorsolateral substantia nigra in SWI sequence in various parkinsonism syndromes, including VaP.","journal-title":"Mov Disord"},{"key":"1019_CR85","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.26584","volume":"31","author":"YJ Bae","year":"2016","unstructured":"Bae YJ, et al. Loss of nigral hyperintensity on 3 tesla MRI of parkinsonism: comparison with (123) I-FP-CIT SPECT. Mov Disord. 2016;31:684\u201392.","journal-title":"Mov Disord"},{"key":"1019_CR86","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2169\/internalmedicine.50.5101","volume":"50","author":"K Kashihara","year":"2011","unstructured":"Kashihara K, Shinya T, Higaki F. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Intern Med. 2011;50:1683\u20137.","journal-title":"Intern Med"},{"key":"1019_CR87","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000350291","volume":"70","author":"K Matsuura","year":"2013","unstructured":"Matsuura K, et al. Neuromelanin magnetic resonance imaging in Parkinson\u2019s disease and multiple system atrophy. Eur Neurol. 2013;70:70\u20137.","journal-title":"Eur Neurol"},{"key":"1019_CR88","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/mds.26182","volume":"30","author":"S Reimao","year":"2015","unstructured":"Reimao S, et al. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson\u2019s disease. Mov Disord. 2015;30:953\u20139.","journal-title":"Mov Disord"},{"key":"1019_CR89","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/0284185117722812","volume":"59","author":"K Kuya","year":"2018","unstructured":"Kuya K, et al. Evaluation of Parkinson\u2019s disease by neuromelanin-sensitive magnetic resonance imaging and (123)I-FP-CIT SPECT. Acta Radiol. 2018;59:593\u20138.","journal-title":"Acta Radiol"},{"key":"1019_CR90","first-page":"1879","volume":"39","author":"J Booij","year":"1998","unstructured":"Booij J, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson\u2019s disease. J Nucl Med. 1998;39:1879\u201384.","journal-title":"J Nucl Med"},{"key":"1019_CR91","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.2967\/jnumed.116.186403","volume":"58","author":"PT Meyer","year":"2017","unstructured":"Meyer PT, Frings L. Rucker, G. & Hellwig, S. (18)F-FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med. 2017;58:1888\u201398.","journal-title":"J Nucl Med"},{"key":"1019_CR92","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(10)70002-8","volume":"9","author":"CC Tang","year":"2010","unstructured":"Tang CC, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010;9:149\u201358.","journal-title":"Lancet Neurol"},{"key":"1019_CR93","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","volume":"10","author":"M Politis","year":"2014","unstructured":"Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014;10:708\u201322.","journal-title":"Nat Rev Neurol"},{"key":"1019_CR94","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO;2-V","volume":"15","author":"HT Benamer","year":"2000","unstructured":"Benamer HT, et al. Correlation of Parkinson\u2019s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15:692\u20138.","journal-title":"Mov Disord"},{"key":"1019_CR95","first-page":"642764","volume":"2015","author":"P Solla","year":"2015","unstructured":"Solla P, et al. Focal (123)I-FP-CIT SPECT abnormality in midbrain vascular parkinsonism. Case Rep Neurol Med. 2015;2015:642764.","journal-title":"Case Rep Neurol Med"},{"key":"1019_CR96","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.parkreldis.2012.03.017","volume":"18","author":"A Antonini","year":"2012","unstructured":"Antonini A, et al. The relationship between cerebral vascular disease and parkinsonism: the VADO study. Parkinsonism Relat Disord. 2012;18:775\u201380.","journal-title":"Parkinsonism Relat Disord"},{"key":"1019_CR97","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-0404.2011.01583.x","volume":"126","author":"D Contrafatto","year":"2012","unstructured":"Contrafatto D, et al. [(123) I]FP-CIT-SPECT asymmetry index to differentiate Parkinson\u2019s disease from vascular parkinsonism. Acta Neurol Scand. 2012;126:12\u20136.","journal-title":"Acta Neurol Scand"},{"key":"1019_CR98","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3174\/ajnr.A3970","volume":"36","author":"TC Booth","year":"2015","unstructured":"Booth TC, et al. The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1. AJNR Am J Neuroradiol. 2015;36:229\u201335.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1019_CR99","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/01616412.2017.1312211","volume":"39","author":"L Brajkovic","year":"2017","unstructured":"Brajkovic L, et al. The utility of FDG-PET in the differential diagnosis of Parkinsonism. Neurol Res. 2017;39:675\u201384.","journal-title":"Neurol Res"},{"key":"1019_CR100","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1600-0404.1996.tb00015.x","volume":"93","author":"H Boecker","year":"1996","unstructured":"Boecker H, et al. Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa. Acta Neurol Scand. 1996;93:387\u201392.","journal-title":"Acta Neurol Scand"},{"key":"1019_CR101","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10072-018-3676-8","volume":"40","author":"S Hwangbo","year":"2019","unstructured":"Hwangbo S, et al. Early- and late-phase (18)F-FP-CIT PET images in vascular parkinsonism due to midbrain infarct. Neurol Sci. 2019;40:1089\u201391.","journal-title":"Neurol Sci"},{"issue":"11","key":"1019_CR102","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1097\/RLU.0000000000002721","volume":"44","author":"Chanwoo Kim","year":"2019","unstructured":"Kim C, Kim DY, Hong IK. Vascular parkinsonism by infarctions at different locations on 18F-FP-CIT PET\/CT. Clin Nucl Med. 2019;44:11.","journal-title":"Clinical Nuclear Medicine"},{"key":"1019_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000050748","volume":"46","author":"H Tohgi","year":"2001","unstructured":"Tohgi H, Takahashi S, Abe T, Utsugisawa K. Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism. Eur Neurol. 2001;46:1\u201310.","journal-title":"Eur Neurol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-019-1019-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-019-1019-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-019-1019-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T21:34:18Z","timestamp":1650404058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-019-1019-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":103,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1007\/s11910-019-1019-7","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"26 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Karen KY Ma and Shi Lin each declare no potential conflicts of interest.Vincent CT Mok is the Medical Advisor of BrainNow Medical Techonology Limited. BrainNow aims to develop and commercialise clinically applicable computer-aided software tools for the diagnosis of dementia and other neurodegenerative diseases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"102"}}